Century Therapeutics, Inc.
IPSC
NASDAQ·Healthcare·Biotechnology·Mkt cap $182.7M
$2.11
▲ +0.96%
P/E
-2.34
Mkt Cap
$182.7M
52-Wk Range
$0.44–$3.04
52-Week Range
$0.44 - $3.04
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 313.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary iPSC-derived CAR cell technology platform
- Allogeneic off-the-shelf approach reducing manufacturing complexity
- Diverse pipeline targeting multiple high-value cancer indications
- Strong intellectual property position in cell therapy space
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Stable outlook
Clinical advancement of lead CNTY-101 program for B-cell lymphoma
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-0.5% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IPSC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 12, 2026
Reported EPS of -$0.17 vs -$0.11 consensus (-54.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-54.5%
Revenue trend · last 8Q
—
—
—
-100%
-100%
-100%
-100%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$791.0K
$4.2M
$109.2M
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Apr 21, 2026
vs Industry
How IPSC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related